Literature DB >> 26647825

Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses.

Amber Miller1, Rebecca Nace2, Camilo Ayala-Breton C2, Michael Steele2, Kent Bailey3, Kah Whye Peng4, Stephen J Russell5.   

Abstract

Antitumor efficacy of oncolytic virotherapy is determined by the density and distribution of infectious centers within the tumor, which may be heavily influenced by the permeability and blood flow in tumor microvessels. Here, we investigated whether systemic perfusion pressure, a key driver of tumor blood flow, could influence the intratumoral extravasation of systemically administered oncolytic vesicular stomatitis virus (VSV) in myeloma tumor-bearing mice. Exercise was used to increase mean arterial pressure, and general anesthesia to decrease it. A recombinant VSV expressing the sodium iodide symporter (NIS), which concentrates radiotracers at sites of infection, was administered intravenously to exercising or anesthetized mice, and nuclear NIS reporter gene imaging was used to noninvasively track the density and spatial distribution of intratumoral infectious centers. Anesthesia resulted in decreased intratumoral infection density, while exercise increased the density and uniformity of infectious centers. Perfusion state also had a significant impact on the antitumor efficacy of the VSV therapy. In conclusion, quantitative dynamic radiohistologic imaging was used to noninvasively interrogate delivery of oncolytic virotherapy, highlighting the critical importance of perfusion pressure as a driver of intratumoral delivery and efficacy of oncolytic viruses.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26647825      PMCID: PMC4817823          DOI: 10.1038/mt.2015.219

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  58 in total

1.  Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus.

Authors:  S A Kopecky; M C Willingham; D S Lyles
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

2.  Expression and activity of human Na+/I- symporter in human glioma cells by adenovirus-mediated gene delivery.

Authors:  J Y Cho; S Xing; X Liu; T L Buckwalter; L Hwa; T J Sferra; I M Chiu; S M Jhiang
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

3.  Viruses as antitumor weapons: defining conditions for tumor remission.

Authors:  D Wodarz
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

4.  Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents.

Authors:  Dominik Wodarz
Journal:  Hum Gene Ther       Date:  2003-01-20       Impact factor: 5.695

5.  Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery.

Authors:  Lawrence M Wein; Joseph T Wu; David H Kirn
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

6.  Pathology: cancer cells compress intratumour vessels.

Authors:  Timothy P Padera; Brian R Stoll; Jessica B Tooredman; Diane Capen; Emmanuelle di Tomaso; Rakesh K Jain
Journal:  Nature       Date:  2004-02-19       Impact factor: 49.962

7.  Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal.

Authors:  Thomas Groot-Wassink; Eric O Aboagye; Yaohe Wang; Nicholas R Lemoine; Andrew J Reader; Georges Vassaux
Journal:  Mol Ther       Date:  2004-03       Impact factor: 11.454

8.  GENIS: gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo.

Authors:  Kenneth N Barton; Donald Tyson; Hans Stricker; Young S Lew; Gregory Heisey; Sweaty Koul; Alberto de la Zerda; Fang-Fang Yin; Hui Yan; Tavarekere N Nagaraja; Kelly Ann Randall; Guk Kim Jin; Joseph D Fenstermacher; Sissy Jhiang; Jae Ho Kim; Svend O Freytag; Stephen L Brown
Journal:  Mol Ther       Date:  2003-09       Impact factor: 11.454

9.  Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.

Authors:  David Dingli; Kah-Whye Peng; Mary E Harvey; Philip R Greipp; Michael K O'Connor; Roberto Cattaneo; John C Morris; Stephen J Russell
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

10.  VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Authors:  David F Stojdl; Brian D Lichty; Benjamin R tenOever; Jennifer M Paterson; Anthony T Power; Shane Knowles; Ricardo Marius; Jennifer Reynard; Laurent Poliquin; Harold Atkins; Earl G Brown; Russell K Durbin; Joan E Durbin; John Hiscott; John C Bell
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

View more
  15 in total

Review 1.  Multiple strategies to improve the therapeutic efficacy of oncolytic herpes simplex virus in the treatment of glioblastoma.

Authors:  Zhengjun Zhou; Junjie Tian; Wenyan Zhang; Wei Xiang; Yang Ming; Ligang Chen; Jie Zhou
Journal:  Oncol Lett       Date:  2021-05-03       Impact factor: 2.967

2.  For the Success of Oncolytic Viruses: Single Cycle Cures or Repeat Treatments? (One Cycle Should Be Enough).

Authors:  Stephen J Russell
Journal:  Mol Ther       Date:  2018-07-18       Impact factor: 11.454

3.  Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.

Authors:  Sébastien A Felt; Valery Z Grdzelishvili
Journal:  J Gen Virol       Date:  2017-12       Impact factor: 3.891

4.  Under Pressure: Elevated Blood Pressure Enhances Targeting of Tumors by Oncolytic Viruses.

Authors:  Leonard W Seymour; Kerry D Fisher
Journal:  Mol Ther       Date:  2016-02       Impact factor: 11.454

5.  Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.

Authors:  Lianwen Zhang; Michael B Steele; Nathan Jenks; Jacquelyn Grell; Lukkana Suksanpaisan; Shruthi Naik; Mark J Federspiel; Martha Q Lacy; Stephen J Russell; Kah-Whye Peng
Journal:  Hum Gene Ther Clin Dev       Date:  2016-09       Impact factor: 5.032

6.  Exercise Training Improves Tumor Control by Increasing CD8+ T-cell Infiltration via CXCR3 Signaling and Sensitizes Breast Cancer to Immune Checkpoint Blockade.

Authors:  Igor L Gomes-Santos; Zohreh Amoozgar; Ashwin S Kumar; William W Ho; Kangsan Roh; Nilesh P Talele; Hannah Curtis; Kosuke Kawaguchi; Rakesh K Jain; Dai Fukumura
Journal:  Cancer Immunol Res       Date:  2021-04-10       Impact factor: 11.151

7.  Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.

Authors:  Joselle Cook; Kah-Whye Peng; Thomas E Witzig; Stephen M Broski; Jose C Villasboas; Jonas Paludo; Mrinal Patnaik; Vincent Rajkumar; Angela Dispenzieri; Nelson Leung; Francis Buadi; Nora Bennani; Stephen M Ansell; Lianwen Zhang; Nandakumar Packiriswamy; Baskar Balakrishnan; Bethany Brunton; Marissa Giers; Brenda Ginos; Amylou C Dueck; Susan Geyer; Morie A Gertz; Rahma Warsame; Ronald S Go; Suzanne R Hayman; David Dingli; Shaji Kumar; Leif Bergsagel; Javier L Munoz; Wilson Gonsalves; Taxiarchis Kourelis; Eli Muchtar; Prashant Kapoor; Robert A Kyle; Yi Lin; Mustaqeem Siddiqui; Amie Fonder; Miriam Hobbs; Lisa Hwa; Shruthi Naik; Stephen J Russell; Martha Q Lacy
Journal:  Blood Adv       Date:  2022-06-14

Review 8.  Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect.

Authors:  Raquel Yokoda; Bolni M Nagalo; Brent Vernon; Rahmi Oklu; Hassan Albadawi; Thomas T DeLeon; Yumei Zhou; Jan B Egan; Dan G Duda; Mitesh J Borad
Journal:  Oncolytic Virother       Date:  2017-11-08

Review 9.  Oncolytic Virotherapy Treatment of Breast Cancer: Barriers and Recent Advances.

Authors:  Amy Kwan; Natalie Winder; Munitta Muthana
Journal:  Viruses       Date:  2021-06-11       Impact factor: 5.048

Review 10.  Designing and building oncolytic viruses.

Authors:  Justin Maroun; Miguel Muñoz-Alía; Arun Ammayappan; Autumn Schulze; Kah-Whye Peng; Stephen Russell
Journal:  Future Virol       Date:  2017-03-31       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.